NGL Fine-Chem Past Earnings Performance
Past criteria checks 3/6
NGL Fine-Chem has been growing earnings at an average annual rate of 7.3%, while the Pharmaceuticals industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 14.7% per year. NGL Fine-Chem's return on equity is 14.8%, and it has net margins of 11.1%.
Key information
7.3%
Earnings growth rate
7.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 14.7% |
| Return on equity | 14.8% |
| Net Margin | 11.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How NGL Fine-Chem makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 3,717 | 414 | 531 | 0 |
| 30 Jun 24 | 3,584 | 420 | 493 | 0 |
| 31 Mar 24 | 3,387 | 413 | 480 | 0 |
| 31 Dec 23 | 3,170 | 380 | 452 | 0 |
| 30 Sep 23 | 2,970 | 343 | 427 | 0 |
| 30 Jun 23 | 2,839 | 285 | 409 | 0 |
| 31 Mar 23 | 2,781 | 205 | 392 | 0 |
| 31 Dec 22 | 2,823 | 183 | 379 | 0 |
| 30 Sep 22 | 2,956 | 220 | 379 | 0 |
| 30 Jun 22 | 3,062 | 313 | 380 | 0 |
| 31 Mar 22 | 3,175 | 499 | 366 | 0 |
| 31 Dec 21 | 3,101 | 570 | 352 | 0 |
| 30 Sep 21 | 3,015 | 646 | 342 | 0 |
| 30 Jun 21 | 2,915 | 665 | 323 | 0 |
| 31 Mar 21 | 2,580 | 567 | 303 | 0 |
| 31 Dec 20 | 2,197 | 427 | 287 | 0 |
| 30 Sep 20 | 1,844 | 261 | 267 | 0 |
| 30 Jun 20 | 1,534 | 125 | 256 | 0 |
| 31 Mar 20 | 1,517 | 83 | 261 | 0 |
| 31 Dec 19 | 1,603 | 153 | 252 | 0 |
| 30 Sep 19 | 1,573 | 183 | 243 | 0 |
| 30 Jun 19 | 1,586 | 204 | 237 | 0 |
| 31 Mar 19 | 1,532 | 201 | 227 | 0 |
| 31 Dec 18 | 1,425 | 164 | 226 | 0 |
| 30 Sep 18 | 1,373 | 165 | 222 | 0 |
| 30 Jun 18 | 1,274 | 158 | 211 | 0 |
| 31 Mar 18 | 1,137 | 126 | 203 | 0 |
| 31 Dec 17 | 1,090 | 124 | 182 | 0 |
| 30 Sep 17 | 1,048 | 124 | 170 | 0 |
| 30 Jun 17 | 972 | 117 | 158 | 0 |
| 31 Mar 17 | 997 | 149 | 156 | 0 |
| 31 Dec 16 | 992 | 142 | 137 | 0 |
| 30 Sep 16 | 959 | 129 | 127 | 0 |
| 30 Jun 16 | 969 | 126 | 124 | 0 |
| 31 Mar 16 | 963 | 114 | 120 | 0 |
| 31 Dec 15 | 956 | 109 | 191 | 16 |
| 30 Sep 15 | 929 | 96 | 188 | 16 |
| 30 Jun 15 | 923 | 94 | 103 | 0 |
| 31 Mar 15 | 883 | 83 | 99 | 0 |
| 31 Dec 14 | 826 | 50 | 146 | 11 |
| 30 Sep 14 | 823 | 53 | 181 | 11 |
| 30 Jun 14 | 783 | 46 | 138 | 11 |
| 31 Mar 14 | 789 | 45 | 136 | 11 |
| 31 Dec 13 | 749 | 50 | 101 | 10 |
Quality Earnings: 524774 has a high level of non-cash earnings.
Growing Profit Margin: 524774's current net profit margins (11.1%) are lower than last year (11.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524774's earnings have grown by 7.3% per year over the past 5 years.
Accelerating Growth: 524774's earnings growth over the past year (20.6%) exceeds its 5-year average (7.3% per year).
Earnings vs Industry: 524774 earnings growth over the past year (20.6%) exceeded the Pharmaceuticals industry 20.5%.
Return on Equity
High ROE: 524774's Return on Equity (14.8%) is considered low.